Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Treasury Shares (2020 - 2025)

Lyell Immunopharma's Treasury Shares history spans 6 years, with the latest figure at $84047.0 for Q3 2025.

  • For Q3 2025, Treasury Shares fell 98.1% year-over-year to $84047.0; the TTM value through Sep 2025 reached $84047.0, down 98.1%, while the annual FY2024 figure was $281190.0, N/A changed from the prior year.
  • Treasury Shares for Q3 2025 was $84047.0 at Lyell Immunopharma, down from $117670.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $9.1 million in Q1 2025 and bottomed at $84047.0 in Q3 2025.
  • The 5-year median for Treasury Shares is $2.6 million (2023), against an average of $2.7 million.
  • The largest annual shift saw Treasury Shares soared 323.92% in 2021 before it plummeted 98.1% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $2.6 million in 2021, then tumbled by 66.46% to $872077.0 in 2022, then soared by 218.44% to $2.8 million in 2023, then tumbled by 89.87% to $281190.0 in 2024, then crashed by 70.11% to $84047.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Treasury Shares are $84047.0 (Q3 2025), $117670.0 (Q2 2025), and $9.1 million (Q1 2025).